$ZSAN in Bullish Crossover

ZSAN President and chief executive officer, Steven Lo, will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 3:00 pm ET. (Possible Catalyst this week) Released earnings last week.

Pt between $2.40 to $3.13

Qtrypta is Zosano's transdermal microneedle product candidate for the acute treatment of migraine. In March, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application for Qtrypta and granted a Prescription Drug User Fee Act (PDUFA) goal date of October 20, 2020.